MEI PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.86 USD | -1.38% |
|
-7.74% | -50.69% |
Valuation
| Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 178.2 | 437.8 | 320.9 | 80.56 | 43.84 | 19.06 | - | - |
| Enterprise Value (EV) 1 | 178.2 | 425.4 | 320.9 | 80.56 | 43.84 | 19.06 | 19.06 | 19.06 |
| P/E ratio | -10.4 x | -8.1 x | -6.33 x | -1.38 x | -1.38 x | 0.79 x | -0.5 x | -0.77 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 36.3 x | 15.1 x | 12.6 x | 1.98 x | 0.9 x | 0.29 x | 3.05 x | 0.76 x |
| EV / Revenue | 36.3 x | 15.1 x | 12.6 x | 1.98 x | 0.9 x | 0.29 x | 3.05 x | 0.76 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -6,013,028 x | 13,121,162 x | -9,821,453 x | -1,636,506 x | - | - | - | - |
| FCF Yield | -0% | 0% | -0% | -0% | - | - | - | - |
| Price to Book | - | - | 7.76 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,565 | 5,300 | 5,630 | 6,658 | 6,663 | 6,663 | - | - |
| Reference price 2 | 50.00 | 82.60 | 57.00 | 12.10 | 6.580 | 2.860 | 2.860 | 2.860 |
| Announcement Date | 8/28/19 | 9/9/20 | 9/2/21 | 9/8/22 | 9/26/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.915 | 28.91 | 25.54 | 40.7 | 48.82 | 65.3 | 6.25 | 25 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -46.24 | -24.54 | -69.68 | -75.48 | -36.76 | 23.16 | -41.13 | -29.35 |
| Operating Margin | -940.9% | -84.88% | -272.9% | -185.48% | -75.31% | 35.48% | -658.13% | -117.41% |
| Earnings before Tax (EBT) 1 | -16.82 | -46.02 | -50.57 | -54.45 | -31.84 | 26.57 | -39.95 | -25.87 |
| Net income 1 | -16.82 | -46.02 | -50.58 | -54.45 | -31.84 | 26.57 | -39.95 | -25.87 |
| Net margin | -342.2% | -159.15% | -198.06% | -133.8% | -65.22% | 40.69% | -639.22% | -103.49% |
| EPS 2 | -4.800 | -10.20 | -9.000 | -8.800 | -4.780 | 3.620 | -5.690 | -3.710 |
| Free Cash Flow | -29.64 | 33.36 | -32.67 | -49.22 | - | - | - | - |
| FCF margin | -603.05% | 115.39% | -127.95% | -120.95% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/28/19 | 9/9/20 | 9/2/21 | 9/8/22 | 9/26/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 18.22 | 9.694 | 11.41 | 8.73 | 32.74 | 5.894 | 1.457 | 65.3 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.24 | -21.56 | -16.2 | -18.22 | 8.926 | -16.39 | -11.08 | 55.28 | -11.93 | -9.829 | -10.87 | -14.8 | -18.8 |
| Operating Margin | -61.66% | -222.38% | -141.9% | -208.69% | 27.27% | -278.1% | -760.47% | 84.66% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.766 | -8.725 | -16.06 | -16.62 | 10.25 | -15.44 | -10.03 | 56.37 | -11.06 | -9.127 | -9.966 | -14.2 | -18.3 |
| Net income 1 | -5.766 | -8.725 | -16.06 | -16.62 | 10.25 | -15.44 | -10.03 | 56.37 | -11.06 | -9.127 | -9.408 | -11.3 | -14.6 |
| Net margin | -31.64% | -90% | -140.73% | -190.42% | 31.32% | -261.93% | -688.33% | 86.33% | - | - | - | - | - |
| EPS 2 | -1.000 | -1.400 | -2.400 | -2.400 | 1.600 | -2.320 | -1.507 | 8.460 | -1.660 | -1.370 | -1.407 | -1.700 | -2.200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/10/22 | 5/23/22 | 9/8/22 | 11/14/22 | 2/9/23 | 5/11/23 | 9/26/23 | 11/9/23 | 2/13/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 12.3 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -29.6 | 33.4 | -32.7 | -49.2 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | -26.4% | - | -22.4% | - | - | - |
| Assets 1 | - | - | 191.9 | - | 142.2 | - | - | - |
| Book Value Per Share | - | - | 7.350 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | -7.880 | - | - | - |
| Capex | 0.22 | 0.89 | 0.71 | 0.48 | - | - | - | - |
| Capex / Sales | 4.42% | 3.09% | 2.77% | 1.18% | - | - | - | - |
| Announcement Date | 8/28/19 | 9/9/20 | 9/2/21 | 9/8/22 | 9/26/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.86
USD
Average target price
22.67
USD
Spread / Average Target
+692.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.69% | 19.06M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- MEIP Stock
- Financials MEI Pharma, Inc.
